CLINORIL (sulindac) by Merck & Co. is clinical pharmacology pharmacodynamics sulindac is a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. Approved for head and neck cancer, fragile x syndrome. First approved in 1978.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CLINORIL (sulindac) is a non-steroidal anti-inflammatory drug (NSAID) approved in 1978 that exhibits anti-inflammatory, analgesic, and antipyretic activity through prostaglandin synthetase inhibition. It is indicated for head and neck cancer and Fragile X Syndrome. The drug is administered orally as a tablet and undergoes hepatic metabolism to both active and inactive metabolites with substantial enterohepatic circulation.
Product is approaching loss of exclusivity with modest linked job count (16), indicating a contracting commercial footprint and reduced team expansion potential.
CLINICAL PHARMACOLOGY Pharmacodynamics Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities in animal models. The mechanism of action, like that of other NSAIDs, is not completely understood but may be related to…
Worked on CLINORIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
CLINORIL roles are concentrated in commercial management and operational support functions, reflecting a legacy product in decline rather than a growth vehicle. Career trajectory on this product is limited; professionals should expect stable but non-expanding responsibilities focused on market maintenance and regulatory compliance.
16 open roles linked to this drug